SPARC receives CRL from USFDA for Latanoprost NDA

02 Dec 2014 Evaluate

U.S. Food and Drug Administration (FDA) has issued a Complete Response letter (CRL) to Sun Pharma Advanced Research Company’s (SPARC’s) New Drug Application (NDA) for Latanoprost BAK-free eyedrops.

While the FDA did not seek any additional information for supporting clinical data, it sought additional information on certain labeling and other deficiencies for processing the NDA.

SPARC believes that this additional information request from the FDA can be addressed on priority. SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

133.75 -0.30 (-0.22%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 654.25
Indegene 522.50
CMS Info Systems 343.20
Sagility 52.23
Smartworks Coworking 472.85
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×